ACADIA Pharmaceuticals Inc.


Company Name:
ACADIA Pharmaceuticals Inc.  
Sector:
Healthcare 
Transaction Type:
Follow-on Offering 
Ticker Symbol:
ACAD 
Deal Amount:
$300M
Transaction Date:
1/7/2016 
Transaction Summary:
ACADIA Pharmaceuticals Inc. raised $300.0 million in its follow-on offering at $29.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares from the offering will be used by ACADIA Pharmaceuticals Inc. . to fund commercialization efforts for NUPLAZID, ongoing and new clinical trials and development efforts for pimavanserin, and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.  
Company Description:
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has a pipeline of product candidates led by NUPLAZID™ (pimavanserin), for which we have submitted a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA and which has the potential to be the first drug approved in the United States for this condition. The FDA has classified the NUPLAZID NDA as having Priority Review status. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. 
Investment Banking